Navigation Links
Chesley Files Class Action Against DePuy Orthopaedics
Date:11/4/2010

CINCINNATI, Nov. 4, 2010 /PRNewswire/ -- Stanley M. Chesley of the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & Chesley Co., L.P.A. earlier today filed a major class action lawsuit against DePuy Orthopaedics, Inc. and Johnson and Johnson (NYSE: JNJ).

DePuy and Johnson and Johnson recently recalled over 90,000 ASR XL Acetabular hip replacement Systems. The system has an unacceptable failure rate causing patients to undergo hip replacement surgery.

DePuy and Johnson and Johnson notified Chesley's client Carolyn Pearcy that she has a recalled ASR XL Acetabular hip system and advised her, similar to other recipients, to undergo a series of tests. Pearcy believes that her recalled hip was the probable cause of her persistent and excruciating pain.

In her action Pearcy seeks court supervised medical monitoring. The goal is to ensure that every recipient receives without cost necessary medical tests. According to Chesley, "DePuy refuses to accept fundamental financial responsibility. It wants patients and their insurance companies to pay for medical tests required because of DePuy's bad hips."

Pearcy also is seeking damages including punitive damages. Chesley commented that "DePuy and J&J were on notice of the defective system, yet continued to manufacture, market and sell it to innocent victims."

For more than 40 years, Stanley M. Chesley and Waite, Schneider, Bayless & Chesley Co., L.P.A. have represented individuals from across the United States in a variety of personal injury, breach of contract, fraud, and negligence claims, including complex product liability cases, toxic exposure, and dangerous prescription drugs.  More information on the firm is found at http://www.wsbclaw.com.

CONTACT:   Stanley M. Chesley or Terrence L. Goodman at (513) 621-0267


'/>"/>
SOURCE Stanley Chesley of Waite, Schneider, Bayless & Chesley Co., L.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Chesley Files Federal Zicam Lawsuits
2. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
3. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
4. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
5. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
6. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
7. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
8. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
9. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
10. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
11. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/13/2017)... has been named the official orthopedic and sports medicine ... 2018 College Football Playoff (CFP) National Championship to be played ... Atlanta, Georgia . OrthoAtlanta is proud to be ... many activities leading up to, and including the national championship ... OrthoAtlanta serves ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/9/2017)... Lilly and Company (NYSE: LLY ) will ... an investigational, oral, first-in-class molecule for the acute treatment ... placebo in the Phase 3 SPARTAN study. Detailed results ... the International Headache Society (IHC) in Vancouver ... lasmiditan,s potential to reduce pain and provide freedom from ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 2017 , ... Collins Concrete Coatings announced that they offer ... safety and cleanliness. This unique flooring system uses silver ion technology to resist ... for its antimicrobial properties. Unlike antibiotics, which kill specific microorganisms, silver ions attack ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... medical device compliance and commercialization, has just released a new white paper ... is more adamant than ever about medical device, pharmaceutical, and combination product ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... customer service and innovation, the company recently unveiled a redesigned website. The new ... enrich the work of building owners, architects, contractors and other industry users that ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot Company ... The goal is to ignite conversation via social media and word-of-mouth regarding vaginal ... has declared September “Humans with Vaginas” month, releasing a video celebrating the power ...
(Date:9/20/2017)... ... September 20, 2017 , ... Health & Safety Institute (HSI) is offering ... 24- and 40-Hour courses from now until November 30, 2017 to assist with the ... discounted prices to all businesses and government agencies – whether or not they will ...
Breaking Medicine News(10 mins):